ejpmr, 2025, 12(1), 355-361

SJIF Impact Factor 7.065

EUROPEAN JOURNAL OF PHARMACEUTICAL AND MEDICAL RESEARCH

www.ejpmr.com

Review Article

ISSN 2394-3211

EJPMR

A REVIEW ON VITILIGO: A FOCUS ON PATHOGENESIS AND ITS SYMPTOMS, CAUSES, DIAGNOSIS, NEW AND EMERGING TREATMENTS AND MEDICATIONS

***Ankush, Sanjyoti, Dr. Neeraj Bandari, Amisha Gautam, Aanchal Chandel, Ankush Sharma, Abhijeet Singh, Ashish Kumar**

Student of B. Pharmacy, School of Pharmacy, Arni University, Kathgarh, Indora, Distt. Kangra H.P. Pin Code 176-401.

***Corresponding Author: Ankush**

Student of B. Pharmacy, School of Pharmacy, Arni University, Kathgarh, Indora, Distt. Kangra H.P. Pin Code 176-401.

Article Received on 25/11/2024 **Article Revised on 15/12/2024** **Article Accepted on 04/01/2025**

ABSTRACT

A frequent DE pigmenting skin condition called vitiligo is defined by an acquired, idiopathic, progressive, confined hypomelanosis of the skin and hair, as well as a microscopic absence of melanocytes. It is a global phenomenon that has an incidence rate ranging from 0.1% to 2%.Vitiligo is a significant skin condition that significantly lowers a patient's quality of life. Although the exact causes of this disorder are unknown, it appears that neurological, immunological, and genetic variables interact to some extent. Other autoimmune diseases, malignant melanoma, and Sutton or halo nevus coexist with vitiligo. Treatment is required because the significant deformity caused by vitiligo can put the patient under a great deal of emotional stress. There are many different treatments available because the pathophysiology is yet unknown. The most popular ones at the moment for treating localized and generalized vitiligo, respectively, were topical prednisone and narrowband UVB monotherapy. Self-tanning dyes and camouflage solutions are two ways to improve your appearance cosmetically. Vitiligo can develop in a variety of ways, but it usually advances. A small percentage (10–20%) of persons, mostly in youngsters, may experience spontaneous repigmentation; however, this usually only happens in parts of the body that have been exposed to sunlight. We review all aspects of vitiligo in this article, including epidemiology, pathogenesis and etiology, histopathology, clinical manifestations, classification, clinical variants, diagnosis, differential diagnosis, targeted research, prognosis, treatment, and psychosocial perspective.[1] A number of illnesses, such as autoimmune, genetic, neurological, viral, and oxidative stress a disorder called vitiligo is recognized for causing the affected area of skin to become paler. Vitiligo is caused by a loss of melanocyte functioning, yet the actual cause of vitiligo is not known. Nonetheless disorders, may play a significant part in vitiligo. Worldwide, vitiligo prevalence is less than 2%. We distinguish between two forms of vitiligo: idiopathic and chemical. Idiopathic vitiligo makes up the bulk of cases. There may also be depigmentation in the hair and mouth mucosa in vitiligo. Non-segmental vitiligo (NSV), also known as generalized vitiligo (GVT), is characterized by white patches that are frequently symmetrical and typically get bigger over time. This is indicative of a significant loss of melanocytes from functional epidermal cells and, in certain circumstances, hair follicles. An acquired chronic pigmentation condition called segmental vitiligo is characterized by unilaterally distributed white patches that may or may not match a dermatome. An acquired chronic pigmentation condition called segmental vitiligo is characterized by unilaterally distributed white patches that may or may not match a dermatome.[2] A chronic, acquired illness called vitiligo is characterized by either melanin loss or degradation or depigmentation of the epidermis. The pigment that gives skin its colour, melanin, is produced by skin cells called melanocytes. The goal of this review is to present a thorough summary of the state of our understanding on vitiligo. Everyone can get vitiligo, even though no one ethnicity, gender, or skin type is more susceptible than others. Systemic and topical phototherapy, immunomodulators such corticosteroids, calcineurin inhibitors, and vitamin D analogues, as well as camouflage-enhancing cosmetics, are the most often prescribed therapies for vitiligo. Despite the common perception of vitiligo as a cosmetic condition, its repercussions on the body and mind The victims' health must be disregarded.[3]

INTRODUCTION

Vitiligo is a condition where a portion of the skin becomes DE pigmented. Although the actual etiology of vitiligo is uncertain, it is caused by a loss of melanocyte activity. Nonetheless, a number of illnesses, such as autoimmune, genetic, neurological, viral, and oxidative stress, may play a significant part in in vitiligo. Less than 2% of people globally have vitiligo. There are two forms of vitiligo: idiopathic and chemical. The idiopathic form of vitiligo White patches that are frequently symmetrical and typically get bigger over time are the hallmark of generalized vitiligo, also known as non-segmental

vitiligo (NSV), which is caused by a significantloss of functional epidermal and occasionally hair follicle melanocytes. A chronic pigmentation condition that is acquired, segmental vitiligo is typified by white patches with a distribution that could partially or completely correspond to a dermatome.[2]

When vitiligo was first mentioned 3,500 years ago in Egyptian and Indian scriptures, the social shame attached to this deformity was already apparent. The Egyptian Ebers Papyrus (1500 bce), the Hebrew Bible's book of Leviticus from around the same period, and the Atharvaveda, an ancient scripture composed in India between 1500 and 1000 bce, all mention white spots on the skin.[6,17]

According to Indian literature, it is "abhorred" for a son or daughter to marry someone who has these white patches. Hindu traditions imply that people with vitiligo may have stolen clothing in their past lives, whereas early Buddhist literature claims that both men and women with the condition were not eligible for ordainment.[6,18]

Patchy skin depigmentation, which can occur on any portion of the body, is a defining feature of vitiligo. About 1% of people worldwide are afflicted, and there is no discernible variation in prevalence based on sex, race, or geographic location.[19]

Vitiligo has a detrimental impact on patients' quality of life, just as it did in the past, by lowering self-esteem and causing severe psychological anguish. This decline in quality of life is similar to those of other debilitating skin conditions such eczema and psoriasis. Skin lesions associated with vitiligo are visible symptoms of the condition that lead to feelings of guilt, anxiety, and despair. Visible areas like the hands and face are frequently impacted, and patients frequently worry that their illness may spread and worsen there.[6]



Fig No 1 Vitiligo on Foot.



Fig No 2 Vitiligo on Foot.

The most prevalent depigmentation disorder is vitiligo, which had a global frequency of 0.06–2.28% in 2012. [4, 20, 21] It is distinguished by the lack of skin pigment, which results from the depletion of melanocytes. The skin, hair follicles, eyes, inner ear, bones, heart, and brain are among the tissues that contain melanocytes. The primary function of the epidermal unit, which is made up of melanocytes in the basal layer of the epidermis and surrounding keratinocytes, is the complex process of melanogenesis, which produces and distributes melanin.[4,22]

There are two types of melanin: pheomelanin, which is reddish-yellow, and eumelanin, which is brown or black. It offers photo protection due to its light-absorbing qualities .Although melanogenesis is genetically determined, genetically, but is also impacted by a number of internal and external circumstances. Among the extrinsic influences are medications and UV radiation. UV light, the melanocortin 1 receptor, and pigment precursors L-tyrosine and L-DOPA are some of the inducers and positive regulators of melanogenesis. It is believed that the latter is the most significant positive regulator.[4, 23 ,24]

Vitiligo has a long history and affects people of all races. Its visual phenotype has allowed for its recognition for thousands of years. It is a prevalent DE pigmenting skin

condition, with a complete lack of melanocytes under a microscope and acquired, idiopathic, progressive, confined hypomelanosis of the skin and hair. A psychologically devastating and often resistant cutaneous condition is vitiligo.[25,26]

Although the exact causes of this illness are unknown, it appears to be influenced by the interplay of neurological, immunological, and genetic variables. Twelve It exhibits polygenic inheritance and complex etiology in general.[27,28]

Vitiligo can have a catastrophic cosmetic and psychological impact, leading to low self-esteem, a negative body image, and trouble in sexual relationships, even though it is neither life-threatening nor symptomatic (except from the fact that DE pigmented patches burn readily in the sun.[1]

Even though numerous recent research have shown that vitiligo affects people of all skin types and ethnicities equally (Fitzpatrick), 35,694 adults over the age of 18 from Europe, Japan, andthe USA were recruited viapanel to answer questions regarding any past skin diseases they may have had, In including vitiligo.

Overall, vitiligo prevalence was assessed to be 1.3%. Those with type III (light brown; 0.5%) and type IV (moderate brown; 0.4%) skin phototypes had the highest prevalence of vitiligo, according to the Fitzpatrick scale. The current understanding of vitiligo is reviewed in this article, along with its aetiology, classification, pathophysiology, diagnosis, and potential therapies.[3]





Pathogenesis: Both hereditary and non-genetic factors contribute to the complex disease known as vitiligo. It is commonly acknowledged that the absence of functioning melanocytes in vitiligo skin results from damage.[1]

According to the biochemical/cytotoxic hypothesis, vitiligo develops when cytotoxic precursors to melanin formation destroy melanocytes. According to the neural hypothesis, segmental vitiligo results from nerve injury that occurs at the areas where neurons interact with melanocytes.[2]

The loss of functioning melanocytes is the hallmark of vitiligo, a complicated disorder. There are several hypothesized explanations for vitiligo's melanocyte loss. This disease can be caused by a variety of factors, including melanocyte separation, oxidative stress, immunological responses, genetics, and inflammatory mediators. Both the innate and adaptive arms of the immune system seem to be active. The various vitiligo phenotypes cannot be well explained by the ideas that have been put forth, and it is still up for question how much each process contributes overall. Nonetheless, everyone agrees that vitiligo is an autoimmune condition.[5]

Genetics of Vitiligo

Although it is evident that these influences are complicated, there is strong evidence from multiple studies indicating hereditary factors play a significant role in the development of vitiligo. Although vitiligo tends to cluster in families, according to extensive epidemiological studies, the hereditary risk is not always present. Nine percent of vitiligo cases have numerous close relatives who also have the condition; these cases are referred to as "multiplex" family clusters. The great majority of vitiligo cases (91%) do not have any known close relatives who have the condition, and these cases are referred to as "simplex."[7]

The genetic makeup of vitiligo has been thoroughly understood because to persistent recent work.[8,9] Approximately 80% of the risk for vitiligo can be attributed to genetic factors, with the other 20% coming from environmental factors.[10,11,4]

Though multiplex vitiligo families have a higher additive risk, the same loci identified in GWAS of mostly simplex cases are involved in the polygenic vitiligo genetic risk in both simplex and multiplex instances.[12] It's interesting to note that vitiligo and melanoma susceptibility appear to be mutually exclusive, pointing to a genetic dysregulation of immunological surveillance against the melanocytic system.[13,14,15]

Although it is evident that these influences are complex, there is strong evidence from numerous studies indicating hereditary factors play a significant role in the development of vitiligo. Vitiligo tends to cluster in families, according to epidemiological research, but the hereditary risk is not always present. About 20% of vitiligo patients have at least one first-degree family who also has the condition, and first-degree relatives are seven to ten times more likely to get vitiligo.[16]

Treatment

Your age, the extent and location of skin involvement, the rate at which the disease is developing, and the way it is impacting your life all influence the treatment option.[29]

Although the results are unexpected and vary, medications and light-based therapies can help restore skin colour or level out skin tone. Additionally, some therapies have detrimental side effects. Therefore, your doctor may advise you to try using makeup or self-tanning products to change the way your skin looks first.[30, 28]

Medications

The loss of pigment cells (melanocytes) that causes vitiligo cannot be stopped by medication. However, several medications can aid in color restoration when used either by alone.[31]

Medications that reduce inflammation: The color of the afflicted skin may return if a corticosteroid lotion is

applied. When vitiligo is still in its early stages, this works well. Although this kind of cream works well and is simple to use, it may take several months before you notice any changes in the color of your skin. Skin thinning or the development of wrinkles or streaks on your skin are examples of potential adverse effects. Children and those with big patches of discolored skin may be offered milder versions of the medication.[32]

Medications that affect the immune system: For those with minor depigmentation, particularly on the face and neck, calcineurin inhibitor ointments such pimecrolimus (Elidel) or tacrolimus (Protopic) may be helpful. The Food and Drug Administration (FDA) in the United States has issued a warning on a potential connection between these medications and skin cancer and lymphoma.[33]

THEARPY

Light treatment. It has been demonstrated that phototherapy using narrow band ultraviolet B (UVB) can either prevent or reduce the course of active vitiligo. It may work better when combined with calcineurin inhibitors or corticosteroids. Therapy will be necessary for you two or three times a week. You might not see any change for one to three months, and it might take six months or more to see the entire impact.[34]

Combining psoralen and light therapy

In order to restore colour to the light patches, this treatment mixes light therapy (photo chemotherapy) with psoralen, a plant-derived chemical. Psoralen exposes you to ultraviolet A (UVA) light once it is taken orally or applied topically. Despite its effectiveness, this method is more challenging to use, and narrow band ultraviolet B (UVB) therapy has supplanted it in many practices.[35]

Removing the remaining colour (depigmentation)

If prior treatments have failed and your vitiligo is widespread, this therapy can be a good option. The skin's unaffected portions are treated with a DE pigmenting chemical. The skin eventually becomes lighter as a result, blending in with the discoloured parts. For at least nine months, the therapy is administered once or twice daily. Redness, swelling, itching, and extremely dry skin are possible side effects. Depigmentation is irreversible.[35,36]

Surgery

Surgery may be an option for certain patients with stable illness if light treatment and medicines have failed. The following methods aim to restore color and balance out skin tone.[37]

Skin Grafting

Small portions of your healthy, pigmented skin are transferred by your doctor to parts of your skin that have lost colour throughout this treatment. This treatment is occasionally applied to minor vitiligo areas.[38]

Blister grafting

This treatment involves your doctor using suction to make blisters on your pigmented skin. Potential dangers include scarring, a cobblestone look, and the area's inability to recolor. Additionally, the suctioning-induced skin injury could result in another vitiligo patch.[39,42,43]

Cellular Suspension Transplant

Your physician will take a sample of your pigmented skin, place the cells in a solution, and then transplant the cells onto the prepared damaged area. Within four weeks, this repigmentation process begins to show effects.[40,44]

CONCLUSION

Vitiligo is a common multifactorial skin disorder with a very complicated pathogenesis. But even with recent significant advances in our knowledge of vitiligo, its origin and pathology remain unclear. To better understand the pathophysiology of vitiligo, more research is required to determine what ultimately leads to melanocyte death. Understanding the biological mediators and molecular mechanisms that lead to metabolic problems, melanocyte degeneration, and autoimmunity is necessary to identify innovative therapeutic targets and medications that may prevent, stop, or treat vitiligo. Targeting cytokines, systemic biological treatments that have been used to treat psoriasis raise the possibility that vitiligo could benefit from a similar strategy. Therefore, using already available or soon-to-be-approved medications that target the IFN-γ-chemokine axis is appealing and promising. Furthermore, a significant issue in the scientific community is the comparability and possible usefulness of upcoming clinical research for vitiligo patients. The outcome measures that are employed in vitiligo RCTs are significantly different. Eleftheriadou et al. found that "repigmentation has been measured in 54 controlled trials using 48 different outcome assessment tools." Eleven outcome measurement instruments are available to evaluate different aspects of vitiligo in response to the aforementioned.

Two global e-Delphi consensus sessions on a core set of vitiligo results were held. They defined a repigmentation success rate of ≥80%. Based on the consensus guidelines created by the Cochrane Skin Group Core Outcome Set Initiative and the Vitiligo Global Issues Consensus Group, three workshops with vitiligo sufferers have recently been held. The Vitiligo Noticeability Scale and the quartiles of the repigmentation percentage (0–25, 26–50, 51–79, and 80 100%) were suggested by the authors. Ultimately, this ongoingendeavor to establish a core set of outcomes will boost confidence in choices about the best course of treatment for patients with vitili go and improve the ability to use trial results for meta-analyses.

REFERENCE

1 Howitz J, Brodthagen H, Schwartz M, Thomsen K. Prevalence of vitiligo. Arch Dermatol 1977; 113: 47-52.
2 Helmy MI, Gayyar EIMA, Hawas S, Eissa EA. Role of oxidative stress in the pathogenesis of vitiligo. J Pan Arab League Dermatologist 2004; 15: 97–105.
3 Spritz RA. The genetics of generalized vitiligo. Curr Dir Autoimmun 2008; 10: 244–257.
4 Huang Cl, Nordlund JJ, Biossy R. Vitiligo: a manifestation of apoptosis? Clin Dermatol 2002; 3: 301–308.
5 Whitton ME, Ashcroft DM, Gonza´lez U. Therapeutic intervention for vitiligo. J Am Acad Dermatol 2008; 59: 713–717.
6 Alkahateeb A, Fain PR, Thody A, Bennett DC, Spritz Ra. Epidemiology of vitiligo and associated auto immune disease in Caucasian probands and their families. Pigment Cell Res., 2003; 16: 208–214.
7 Torello L, Alessia G, Zanieri F, Colucci R, Moretti S. Vitiligo: new and emerging treatments. Dermatol Ther., 2008; 21: 110–117.
8 Moretti S, Amato L, Bellandi S, Fabbri P. Focus on vitiligo: a generalized skin disorder. Eur J Inflamm., 2006; 4: 21–30.
9 Szczurko O, Boon HS. A systematic review of natural heath product treatment for vitiligo. BMC Dermatol 2008; 8: 2.
10 Aghaei SH, Sodaifi M, Jafari P, Mazharinia N, Finlay AY. DLQI scores in vitiligo: reliability and validity of the Persian version. BMC Dermatol, 2004; 4: 8.
11 Lerner AB. On the etiology of vitiligo and grey hair. Am J Med., 1971; 51: 141–147.
12 Chan S, Gerson B, Subramaniam S. The role of cop per, molybdenum, selenium, and zinc in nutrition and health.Clin Lab Med., 1998; 18: 673–685.
13 Gokhale BB, Mehta LN. Histopathology of vitiliginous skin. Int J Dermatol, 1983; 22: 477–480.
14 Ogg GS, Dunbat PR, Romero P, Chen JL, Cerundulo V. High frequency of skin homing melanocyte-specific cytotoxic T lymphocytes in autoimmune vitiligo. J Exp Med., 1998; 188: 1203–1208.
15 Le Poole IC, Luiten RM. Autoimmune etiology of generalized vitiligo. Curr Dir Autoimmun, 2008; 10: 227–243.
16 Kwinter J, Pelletier J, Khambalia A and Pope E: High-potency steroid use in children with vitiligo: A retrospective study. J Am Acad Dermatol. 2007; 56: 236-241.
17 Tsuji T and Hamada T: Topically administered fluorouracil in vitiligo. Arch Dermatol, 1983; 119: 722-727.
18 Felsten LM, Alikhan A and Petronic-Rosic V: Vitiligo: A comprehensive overview Part II: Treatment options and approach to treatment. J Am Acad Dermatol, 2011; 65: 493-514.
19 Abd-Elazim NE, Yassa HA and Mahran AM: Microdermabrasion and topical tacrolimus: A novel combination therapy of vitiligo. J Cosmet Dermatol, 2020; 19: 1447-1455.
20 Rodríguez-Martín M, García Bustínduy M, Sáez Rodríguez M and Noda Cabrera A: Randomized, double-blind clinical trial to evaluate the efficacy of topical tacalcitol and sunlight exposure in the treatment of adult nonsegmental vitiligo. Br J Dermatol, 2009; 160: 409-414.
21 Kim SM, Lee HS and Hann SK: The efficacy of low-dose oral corticosteroids in the treatment of vitiligo patients. Int J Dermatol, 1999; 38: 546-550.
22 Seiter S, Ugurel S, Tilgen W and Reinhold U: Use of high-dose methylprednisolone pulse therapy in patients with progressive and stable vitiligo. Int J Dermatol, 2000; 39: 624-627.
23 Radmanesh M and Saedi K: The efficacy of combined PUVA and low-dose azathioprine for early and enhanced repigmentation in vitiligo patients. J Dermatolog Treat, 2006; 17: 151-153.
24 Taneja A, Kumari A, Vyas K, Khare AK, Gupta LK and Mittal AK: Cyclosporine in treatment of progressive vitiligo: An open-label, single-arm interventional study. Indian J Dermatol Venereol Leprol., 2019; 85: 528-531.
25 Skobowiat C and Slominski AT: UVB activates hypothalamic-pituitary-adrenal axis in C57BL/6 Mice. J Invest Dermatol, 2015; 135: 1638-1648.
26 Fecher LA, Agarwala SS, Hodi FS, Weber JS. 2013. Ipilimumab and its toxicities: a multidisciplinary approach. Oncologist, 18(6): 733–43.
27 Nishimura EK. 2011. Melanocyte stem cells: a melanocyte reservoir in hair follicles for hair and skin pigmentation. Pigment Cell Melanoma Res., 24(3): 401–10.
28 James EA, Pietropaolo M, Mamula MJ. 2018. Immunerecognition of β-cells: neoepitopes as key players in the loss of tolerance. Diabetes, 67(6): 1035–42.
29 Boissy RE, Liu Y-Y, Medrano EE, Nordlund JJ. 1991. Structural aberration of the rough endoplasmic reticulum and melanosome compartmentalization in long-term cultures of melanocytes from vitiligo patients. J. Investig. Dermatol, 97(3): 395–404.
30 Rashighi M, Agarwal P, Richmond JM, Harris TH, Dresser K, et al. 2014. CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo. Sci. Transl. Med., 6(223): 223ra23.
31 Jin, Y., Andersen, G., Yorgov, D., Ferrara, T.M., Ben, S., Brownson, K.M., Holland, P.J., Birlea, S.A., Siebert, J., Hart mann, A., et al. (2016). Genome-wide association studies of autoimmune vitiligo identify 23 new risk loci and high light key pathways and regulatory variants. Nat. Genet., 48: 1418–1424.
32 Ermis, O.; Alpsoy, E.; Cetin, L.; Yilmaz, E. Is the efficacy of psoralen plus ultraviolet A therapy for vitiligo enhanced by concurrent topical calcipotriol?

A placebo-controlled double-blind study. Br. J. Dermatol, 2001; 145: 472–475.
33 Yones, S.S.; Palmer, R.A.; Garibaldinos, T.M.; Hawk, J.L. Randomized double-blind trial of treatment of vitiligo: Efficacy of psoralen–UV-A therapy vs narrowband–UV-B therapy. Arch. Dermatol, 2007; 143: 578–584.
34 Tomita, Y.; Torinuki, W.; Tagami, H. Stimulation of human melanocytes by vitamin D 3 possibly mediates skin pigmentation after sun exposure. J. Investig. Dermatol, 1988; 90: 882–884.
35 Rajatanavin, N.; Suwanachote, S.; Kulkollakarn, S. Dihydroxyacetone: A safe camouflaging option in vitiligo. Int. J. Dermatol, 2008; 47: 402–406.
36 Jha, A.K.; Karki, S. Pigmentary disorders; vitiligo and melasma in context of south asian countries: A psychosocio-cosmetic challenge. Int. J. Dermatol. Clin. Res., 2015; 1: 24–30.
37 Gloster, H.M., Jr.; Neal, K. Skin cancer in skin of color. J. Am. Acad. Dermatol, 2006; 55: 741–760.
38 Picardo, M.; Dell'Anna, M.L.; Ezzedine, K.; Hamzavi, I.; Harris, J.E.; Parsad, D.; Taieb, A. Vitiligo (Primer). Nat. Rev. Dis. Prim., 2015; 1: 1–16.
39 Kemp, E.H.; Waterman, E.A.; Weetman, A.P. Autoimmune aspects of vitiligo. Autoimmunity, 2001; 34: 65–77.
40 Korkij, W.; Solatani, K.; Simjee, S.; Marcincin, P.G.; Chuang, T.Y. Tissue-specific autoantibodies and autoimmune disorders in vitiligo and alopecia areata: A retrospective study. J. Cutan. Pathol., 1984; 11: 522–530.
41 S Anirudh, Neeraj Bhandari, Aman Sharma, Ashish Kumar, Ajay kumar IJNRD 9(11/11/2024): 10.
42 Soni, A., Kumar, A., Kumar, A., & Choudhary, A. (2021). New Era of Formulation as Silver Nanoparticles in Pharma. Journal of Drug Delivery and Therapeutics, 11(2-S): 126-131.
43 Kumar, A., Soni, A., Kumar, A., & Devi, J. (2022). Preparation of Luliconazole loaded silver nanoparticles Topical gel. Journal of Drug Delivery and Therapeutics, 12(4): 31-35.
44 Kumar, A., Kumar, A., Soni, A., & Devi, J. (2022). Development and in-vitro evaluation of itraconazole loaded nanoemulsion. Journal of Drug Delivery and Therapeutics, 12(3): 31-42.